Pfizer nets first AIDS patent in India

Pfizer cleared a big milestone in India today: The company became the first to get patent protection for an AIDS drug there. The new patent covers Celzentry, or maraviroc, a new, first-in-class HIV remedy that was approved by the U.S. FDA in August.

Pfizer's victory follows several other attempts, including GlaxoSmithKline's bid for a patent on Combivir; opposition from patient groups prompted GSK to withdraw its application last year.

- read the report from the Economic Times
- see this chart of HIV drug patent applications and their status in the Business Standard

Suggested Articles

CEPI, which started to help prepare the world for new outbreaks, has awarded Inovio and Moderna money for vaccine work against the new coronavirus.

The real estate impresario that built a chain of upscale drug recovery facilities is now building a gene and cell therapy CDMO near Philadelphia.

The seven-year Astellas venture served as a model for Amgen's recent $2.7 billion tie-up with BeiGene in China—and now it's amping up there, too.